Subjects: CARCINOMA DE CÉLULAS ESCAMOSAS, NEOPLASIAS DE CABEÇA E PESCOÇO, ANTICORPOS MONOCLONAIS, ANTINEOPLÁSICOS
ABNT
BURTNESS, Barbara et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, v. 394, n. 10212, p. 1915-1928, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)32591-7. Acesso em: 06 out. 2024.APA
Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 394( 10212), 1915-1928. doi:10.1016/S0140-6736(19)32591-7NLM
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7Vancouver
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7